IPO
Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings
Auris Medical Holding Ltd. announced the pricing of an underwritten public offering of: (i) 330,000 common shares together with warrants to purchase 330,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares.
Funding to scale-up company’s proprietary technology C-Stem™ for mass-production of safe and affordable cell therapies
MyoKardia, Inc. reported financial results for the quarter ended March 31, 2019.
Neos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019 and provided a business update.
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease.
Expedeon AG reported results for the first quarter ended March 31, 2019.
Assertio Therapeutics, Inc. reported financial results for the quarter ended March 31, 2019, and provided an update on its business performance and strategic initiatives.
TLC announced financial results for the first quarter ended March 31, 2019, and provided a business update.
Esperion provided bempedoic acid franchise development program updates and financial results for the first quarter ended March 31, 2019.
PRESS RELEASES